Chk2 Inhibitors - Cancer Science

Relevant Publications

Simulated microgravity induces DNA damage concurrent with impairment of DNA repair and activation of cell-type specific DNA damage response in microglial and glioblastoma cells.

Issue Release: 2024

Advancing cancer therapy: new frontiers in targeting DNA damage response.

Issue Release: 2024

Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.

Issue Release: 2024

Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.

Issue Release: 2024

Chk2 sustains PLK1 activity in mitosis to ensure proper chromosome segregation.

Issue Release: 2024

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.

Issue Release: 2024

Investigation into the Neuroprotective and Therapeutic Potential of Plant-Derived Chk2 Inhibitors.

Issue Release: 2024

Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.

Issue Release: 2024

Assessment of Kinome-wide Activity Remodeling Upon Picornavirus Infection.

Issue Release: 2024

Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights.

Issue Release: 2024

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.

Issue Release: 2024

Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.

Issue Release: 2024

Correlation between Molecular Docking and the Stabilizing Interaction of HOMO-LUMO: Spirostans in CHK1 and CHK2, an In Silico Cancer Approach.

Issue Release: 2024

Bisphenol A exposure inhibits vascular smooth muscle cell responses: involvement of proliferation, migration, and invasion.

Issue Release: 2023

Baicalein Induces G/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells.

Issue Release: 2023

Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway.

Issue Release: 2023

Endogenous PTEN acts as the key determinant for mTOR inhibitor sensitivity by inducing the stress-sensitized PTEN-mediated death axis in KSHV-associated malignant cells.

Issue Release: 2023

DNA damage triggers squamous metaplasia in human lung and mammary cells via mitotic checkpoints.

Issue Release: 2023

Plumbagin Exhibits Genotoxicity and Induces G2/M Cell Cycle Arrest via ROS-Mediated Oxidative Stress and Activation of ATM-p53 Signaling Pathway in Hepatocellular Cells.

Issue Release: 2023

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?

Issue Release: 2023

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics